Has Science Found a Cure for Alcoholism in Ozempic?

Ozempic started as a diabetes medication, became a weight-loss phenomenon, and is now raising a very different question in addiction research: could the same brain-and-reward pathways it affects also influence alcohol use? That possibility has moved from anecdotal reports and animal studies into human clinical trials, making semaglutide one of the more closely watched emerging ideas in alcohol use disorder research. The search for a cure for alcoholism in Ozempic has produced a legitimate new field of research, but people struggling with alcohol today should not delay proven alcohol addiction treatment while waiting to see where the science leads.

Why Are Researchers Studying Semaglutide for Alcohol Use Disorder?

Semaglutide is a GLP-1 receptor agonist best known for its effects on blood sugar, appetite, and food intake. Researchers became interested in its potential role in alcohol use disorder because GLP-1 receptors are also involved in brain systems linked to reward, motivation, and consumption. That does not mean semaglutide simply “switches off” the desire to drink. Alcohol cravings can be influenced by stress, habits, environmental cues, withdrawal, and learned associations, so AUD is far more complex than a single biological pathway.

What Does the Latest Research on Semaglutide and Alcohol Show?

The evidence changed significantly in 2025 when researchers published the first randomized clinical trial showing that semaglutide affected several alcohol-related outcomes in people with AUD. A second randomized trial published in 2026 added more evidence and also showed why it is too early to describe semaglutide as a breakthrough treatment.

The 2025 Once-Weekly Semaglutide Trial

Hendershot and colleagues conducted a phase 2 randomized clinical trial involving 48 adults with alcohol use disorder. Participants received either low-dose, once-weekly semaglutide or placebo during nine weeks of outpatient research participation (Hendershot et al., 2025).

Semaglutide significantly reduced:

• the amount of alcohol consumed during a laboratory drinking test;
• drinks per drinking day;
• weekly alcohol craving; and
• heavy drinking over time compared with placebo.

However, semaglutide did not significantly change average drinks per calendar day or the number of drinking versus abstinent days. That distinction is important. The study suggests participants may have consumed less when they drank, but semaglutide did not simply cause people to stop drinking. The researchers described the findings as initial evidence supporting larger trials rather than proof that semaglutide should already be used routinely for AUD (Hendershot et al., 2025).

The 2026 Oral Semaglutide Trial

A second phase 2 randomized study published in the American Journal of Psychiatry in 2026 examined 50 treatment-seeking adults with moderate-to-severe AUD (Schacht et al., 2026). Participants received either oral semaglutide or placebo for eight weeks.

Semaglutide produced a statistically significant reduction in heavy drinking days, but it did not significantly improve the study’s primary laboratory measure of alcohol cue-induced craving or drinks per day compared with placebo (Schacht et al., 2026).

This is exactly why the evidence needs careful interpretation.

Two randomized studies now suggest that semaglutide can affect some aspects of drinking behavior. But neither study demonstrated that it cures AUD, creates reliable abstinence, prevents relapse, or consistently improves every measure of craving and alcohol consumption.

What Do the Semaglutide Results Actually Mean?

The most reasonable interpretation in 2026 is that semaglutide is promising, but the evidence is preliminary and mixed. So far, randomized studies indicate that the medication may influence how heavily some people drink. The 2025 trial also detected a reduction in weekly alcohol craving, while the 2026 trial found an improvement in heavy drinking days without a significant benefit on its primary laboratory craving outcome.

Several major questions remain unanswered:

• Would similar effects appear in much larger and more diverse groups?
• How long would any reduction in drinking last?
• Would higher or different doses produce different outcomes?
• Which people with AUD would be most likely to benefit?
• Would semaglutide improve long-term abstinence or relapse outcomes?
• How would it compare directly with established AUD medications?

Until larger trials answer these questions, describing Ozempic as a cure for alcoholism would go considerably beyond the evidence.

This caution is especially important because heavy drinking itself can lead to immediate risks such as alcohol poisoning, as well as cumulative physiological effects of alcohol affecting multiple organ systems. Someone with significant alcohol dependence needs appropriate care now rather than relying on an experimental use of another medication.

How Does Semaglutide Compare With Current Alcohol Addiction Medications?

Semaglutide should also be understood in the context of treatments that already exist. SAMHSA identifies naltrexone, acamprosate, and disulfiram as established medications used for alcohol use disorder. These medications work differently and are selected based on an individual’s health, drinking pattern, treatment goals, and other clinical considerations (Substance Abuse and Mental Health Services Administration [SAMHSA], n.d.).

• Naltrexone can reduce some of alcohol’s rewarding effects and help reduce alcohol use.
• Acamprosate is used to support recovery after someone has stopped drinking and may help reduce the likelihood of returning to alcohol.
• Disulfiram works differently: drinking alcohol while taking it produces an unpleasant physical reaction, helping discourage alcohol consumption.

None of these medications is a universal cure either. AUD treatment is individualized, and medication is typically considered alongside behavioral therapy, counseling, recovery support, and other services.

Semaglutide is interesting because it represents a different potential biological pathway, but it does not yet have the same established role in AUD care.

Why Isn’t Semaglutide Considered an AUD Treatment Yet?

Promising trial results are only one step in medication development. The two randomized semaglutide trials involved a combined total of fewer than 100 participants. Treatment lasted only several weeks, and the studies differed in formulation, population, outcomes, and research design. Researchers still need larger trials capable of determining both effectiveness and safety in people specifically seeking treatment for alcohol use disorder.

There are also medical considerations unrelated to AUD. According to the current Ozempic prescribing information, common adverse reactions include nausea, vomiting, diarrhea, abdominal pain, and constipation. The label also includes warnings and precautions concerning conditions such as pancreatitis, severe gastrointestinal reactions, gallbladder disease, and other risks, as well as a boxed warning concerning thyroid C-cell tumors based on rodent findings (FDA, 2026).

Ozempic is therefore not something a person should begin using independently in an attempt to reduce alcohol consumption.

The situation becomes even more important when multiple substances or medications are involved. Anyone using prescription medication while drinking should discuss the specific combination with a healthcare professional rather than assuming it is safe; the dangers of combining drugs and alcohol vary considerably depending on the substance.

Could Semaglutide Eventually Become a Medication for AUD?

Possibly. That is now a scientifically reasonable question. The research has progressed from animal models and anecdotal observations to two randomized phase 2 trials in humans. That is meaningful progress.

At the same time, medication development often produces early findings that change as larger studies are completed. The next stage is not to declare a cure but to determine whether the signal found in these relatively small trials holds up in broader populations and produces clinically meaningful long-term outcomes.

Future studies may also help researchers understand whether particular characteristics, such as drinking pattern, AUD severity, metabolic health, or individual biological differences, influence who responds to GLP-1 receptor agonists.

The broader significance may extend beyond semaglutide itself. Research into GLP-1 pathways could identify new biological targets for addiction medications even if the final treatment ultimately looks different from Ozempic.

Ozempic Is Not a Substitute for Alcohol Addiction Treatment

The attention surrounding semaglutide should not obscure something more important: effective treatment for alcohol use disorder already exists. AUD can involve physical dependence, behavioral reinforcement, emotional triggers, mental health conditions, relationship problems, and serious medical consequences. Medication may address part of that picture, but comprehensive care often needs to address several dimensions at once.

For some people, treatment can include behavioral therapies, established AUD medications, structured recovery support, and planning for triggers and relapse risk. The appropriate combination depends on the individual’s needs.

This also matters when someone is considering quitting alcohol. Abruptly stopping after prolonged heavy drinking can produce medically dangerous withdrawal in some people, so seeking professional guidance is important when physical dependence may be present.

The Current Verdict on a Cure for Alcoholism in Ozempic

There is currently no proven cure for alcoholism in Ozempic. What scientists have found is more nuanced and more credible. Those findings justify larger studies. They do not yet establish semaglutide as a standard AUD medication, and they certainly do not mean that Ozempic has cured alcohol addiction. For people struggling now, established treatment remains the better-supported path. Bright Futures Treatment Center provides professional support for alcohol and substance use disorders and can help determine what level of treatment may be appropriate.

References

Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., & Leggio, L. (2023). The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight, 8(12), e170671. https://doi.org/10.1172/jci.insight.170671

Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., McKee, S. A., Fletcher, P. J., Claus, E. D., & Klein, K. R. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 82(4), 395–405. https://doi.org/10.1001/jamapsychiatry.2024.4789

Schacht, J. P., Sakai, J. T., Raymond, K., & Shelton, R. (2026). Oral semaglutide for alcohol use disorder: A randomized clinical trial. American Journal of Psychiatry, 183(9), 636–645. https://doi.org/10.1176/appi.ajp.20260003

Substance Abuse and Mental Health Services Administration. (n.d.). Treatment options for substance use disorder. https://www.samhsa.gov/substance-use/treatment/options

U.S. Food and Drug Administration. (2026). Ozempic (semaglutide) injection: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf

FAQs

Is Ozempic a cure for alcoholism?

No. Ozempic is not a cure for alcohol use disorder, and semaglutide is not currently an established AUD medication. Early randomized trials suggest semaglutide may reduce some drinking outcomes, but the studies are still small and do not show that it produces long-term remission, prevents relapse, or consistently eliminates alcohol cravings.

Can semaglutide reduce alcohol cravings?

Possibly. A 2025 randomized trial found that once-weekly semaglutide reduced weekly alcohol craving compared with placebo. However, a separate 2026 trial of oral semaglutide did not significantly improve its primary laboratory measure of alcohol cue-induced craving. More research is needed to determine how reliably semaglutide affects cravings.

What did the 2025 and 2026 Ozempic alcohol studies find?

The 2025 trial found reductions in drinks per drinking day, weekly alcohol craving, and heavy drinking over time. The 2026 trial found a significant reduction in heavy drinking days but no significant improvement in drinks per day or its primary craving measure. Together, the studies suggest potential benefits but also show that semaglutide does not improve every alcohol-related outcome.

What medications are currently used to treat alcohol use disorder?

Established medications for alcohol use disorder include naltrexone, acamprosate, and disulfiram. They work in different ways and may be used alongside counseling, behavioral therapy, and other recovery support depending on the individual's health, drinking pattern, and treatment goals.

Can Ozempic replace alcohol rehab or therapy?

No. Even if future research confirms a role for semaglutide in treating AUD, medication would not address every aspect of alcohol addiction. Evidence-based care may include medical assessment, behavioral therapy, established AUD medications, recovery support, and treatment for co-occurring mental health or medical conditions.

Should someone take Ozempic to help them stop drinking?

Ozempic should not be started or used specifically to reduce alcohol consumption without guidance from a qualified healthcare professional. Semaglutide has potential side effects and medical risks, and its optimal dose, duration, and long-term effectiveness for AUD have not yet been established.